5-HT3 receptor antagonists ameliorate fatigue: so much potential, so little knowledge!

Barnes, N. M.
August 2005
Gut;Aug2005, Vol. 54 Issue 8, p1056
Academic Journal
There is growing evidence that 5-HT3 receptor blockade will benefit patients with fatigue. Further research is needed to determine the mechanism underlying this widespread clinically important symptom and therapies may be derived from targeting the 5-HT system.


Related Articles

  • Patient compliance with SSRIs and tricyclic antidepressants.  // American Family Physician;10/1/1995, Vol. 52 Issue 5, p1563 

    Reports on a study from the June 3, 1995 issue of the `British Medical Journal,' by Anderson and Tomenson who conducted a meta-analysis comparing patient compliance rates associated with tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRI). Discontinuation of medication...

  • SSRIs found to drive sexual side effects. Gebhart, Fred // Drug Topics;12/11/95, Vol. 139 Issue 23, p48 

    Reports on the alleviation of the widespread sexual side effects of Prozac and other selective serotonin reuptake inhibitors (SSRIs) by small doses of dextroamphetamine or of methylphenidate. SSRIs' interference with stages of sexual response cycle; Reduction of dosage since sexual effects are...

  • Cardiac effects in patients using SSRI antidepressants. Huffman, Grace Brooke // American Family Physician;8/1/1997, Vol. 56 Issue 2, p612 

    Presents a review on the safety of selective serotonin reuptake inhibitors (SSRI) in terms of cardiovascular side effects by YI Sheline from `American Journal of Medicine,' dated 1997. Information about antidepressants; How the study was done; Conclusion.

  • Lower BMD Z-scores seen with SSRI use.  // Reactions Weekly;7/10/2010, Issue 1309, p3 

    The article discusses a research study which found that the use of selective serotonin reuptake inhibitor (SSRI) may induce low bone mineral density (BMD) Z-scores in adolescents and young adult women with anorexia nervosa.

  • Results of switching to milnacipranin fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Bateman, Lucinda; Palmer, Robert H.; Trugman, Joel M.; Yuhua Lin // Journal of Pain Research;2013, Vol. 6, p311 

    Background: The purpose of this study was to evaluate the safety, tolerability, and efficacy of milnacipran following a direct switch from duloxetine in fibromyalgia patients experiencing inadequate clinical response to duloxetine after receiving treatment for 6 weeks or longer. Methods: This...

  • Dapoxetine: a guide to its use in premature ejaculation.  // Drugs & Therapy Perspectives;Feb2011, Vol. 27 Issue 2, p1 

    Dapoxetine, a selective serotonin reuptake inhibitor, is indicated for the treatment of premature ejaculation in men aged 18-64 years. In well designed clinical trials in men with premature ejaculation, treatment with dapoxetine significantly increased intravaginal ejaculation latency times...

  • Insensitivity of NMRI mice to selective serotonin reuptake inhibitors in the tail suspension test can be reversed by co-treatment with 5-hydroxytryptophan. Jacobsen, Jacob; Nielsen, Elsebet; Hummel, Rene; Redrobe, John; Mirza, Naheed; Weikop, Pia // Psychopharmacology;Aug2008, Vol. 199 Issue 2, p137 

    Exploring differences between mouse strains in drug effects in models of antidepressant-like activity may provide clues to the neurobiology of antidepressant responses. The objective of this study was to explore whether insensitivity to selective serotonin reuptake inhibitors (SSRIs) in NMRI...

  • Psychopharmacology for the Clinician. Young, Simon N. // Journal of Psychiatry & Neuroscience;Nov2003, Vol. 28 Issue 6, p471 

    Features questions related to psychopharmacology for the clinician. Issue of the effectiveness of S-adenosylmethionine (SAMe) and 5-hydroxytryptophan (5-HTP) as natural, over-the-counter alternative to Selective Serotonin Re-uptake Inhibitor (SSRI) for the treatment of depression; Discussion on...

  • Clomipramine enhances the cortisol response to 5-HTP: implications for the therapeutic role of 5-HT[sub 2] receptors. Sargent, P. A.; Quested, D. J.; Cowen, P. J. // Psychopharmacology;1998, Vol. 140 Issue 1, p120 

    Abstract We measured the cortisol response to the 5-HT precursor, 5-hydroxytryptophan, (5-HTP) in seven patients with major depression before and after 8 weeks treatment with the tricyclic antidepressant, clomipramine. The cortisol response to 5-HTP was significantly increased following...


Read the Article


Sign out of this library

Other Topics